Nuvectis Pharma’s ciprocopan approval validates its Haisco deal but raises the execution stakes

Nuvectis Pharma Inc. (Nasdaq: NVCT) has gained a strategically important validation for its newly expanded pipeline after ciprocopan, also known as NXP100, received its first marketing approval in China. China’s National Medical Products Administration approved the once-daily oral Complement Factor B inhibitor for patients with paroxysmal nocturnal hemoglobinuria who had not previously received complement inhibitor therapy. The decision strengthens the commercial argument behind the licensing transaction Nuvectis Pharma completed with Haisco Pharmaceutical Group only one month earlier. However, Nuvectis Pharma does not control ciprocopan’s commercialization in China, meaning the approval validates the asset without immediately creating a direct Chinese revenue stream for the company. Nuvectis Pharma shares were trading near $18.86 late Thursday morning, down approximately 2.3% and about 5.7% below the price of the company’s recent public offering, indicating that investors remain focused on the cost and complexity of translating the Chinese approval into commercial value elsewhere.

Why ciprocopan’s China approval materially strengthens the Nuvectis Pharma investment case

The China approval changes ciprocopan from a licensed clinical-stage asset into a medicine that has successfully crossed a national regulatory threshold. That distinction matters because Nuvectis Pharma acquired its rights to NXP100 before the drug had received approval in any market. The decision therefore reduces some of the scientific and regulatory uncertainty that existed when the company signed the Haisco Pharmaceutical Group agreement in June 2026, even though regulators in the United States, Europe and other territories will conduct their own independent reviews.

The approval was supported by a head-to-head Phase 3 study comparing ciprocopan with AstraZeneca’s Soliris, or eculizumab, in treatment-naive patients with paroxysmal nocturnal hemoglobinuria. Ciprocopan reached a hemoglobin target of 12 grams per deciliter in 59.5% of patients, compared with 8.3% for eculizumab. The average hemoglobin increase was approximately 5.0 grams per deciliter with ciprocopan and 2.2 grams per deciliter with eculizumab, while 94.6% of ciprocopan patients avoided transfusions compared with 69.4% of patients receiving eculizumab. Those results give Nuvectis Pharma a stronger clinical package to present in future regulatory discussions and potential partnership negotiations.

The once-daily dosing schedule could also become a commercially useful point of differentiation. Novartis already markets Fabhalta, or iptacopan, as a twice-daily oral Factor B inhibitor for adults with paroxysmal nocturnal hemoglobinuria in the United States. Ciprocopan is therefore not entering an uncontested market, but its less frequent dosing may appeal to patients who require continuous treatment over many years, provided Nuvectis Pharma can demonstrate comparable efficacy, safety and reliability in the populations required by Western regulators.

The commercial opportunity extends beyond taking share from injectable complement inhibitors. Factor B inhibition targets the alternative complement pathway further upstream than anti-C5 therapies, creating the possibility of controlling both intravascular and extravascular hemolysis. Nuvectis Pharma also sees potential for ciprocopan in other complement-mediated diseases, although those additional indications remain development opportunities rather than established sources of value. The China approval improves the credibility of that platform thesis, but every new indication would still require capital, clinical evidence and regulatory execution.

A second Chinese marketing application covering patients who were previously treated with anti-C5 therapies remains under review. A favorable decision could broaden ciprocopan’s addressable PNH population and provide more evidence about its ability to serve patients switching from established treatments. For Nuvectis Pharma, that outcome could strengthen the package available for ex-China development, even though the associated Chinese sales would remain within Haisco Pharmaceutical Group’s territory.

How the Haisco licensing economics and $100 million offering shape the NXP100 opportunity

Nuvectis Pharma secured exclusive rights to develop, manufacture and commercialize NXP100 across most markets outside Greater China, India and several Southeast Asian countries. Haisco Pharmaceutical Group retained responsibility for ongoing Chinese development and commercialization. Nuvectis Pharma therefore benefits from the clinical and regulatory work completed by Haisco Pharmaceutical Group, but its economic return depends primarily on obtaining approvals and building sales in territories where the company holds rights.

The agreement requires Nuvectis Pharma to pay Haisco Pharmaceutical Group $20 million upfront, with up to another $20 million tied to specified early development events. Haisco Pharmaceutical Group is also eligible for as much as $1.4 billion in additional development, regulatory and commercial milestone payments across NXP100 and the licensed BRAF inhibitor NXP200. The agreement includes tiered royalties ranging from the high-single digits to the mid-teens on net sales, as well as a share of sublicensing revenue.

These terms illustrate why the China approval is important but not sufficient. Ciprocopan must produce enough revenue in the licensed territories to cover clinical development, regulatory submissions, manufacturing, commercialization, royalties and milestone obligations. A successful drug can support those payments, but a delayed or narrowly approved product could leave Nuvectis Pharma carrying significant development costs without achieving the scale required to generate attractive returns.

The agreement also requires a low-double-digit payment based on the fair market value of the licensed rights if Nuvectis Pharma undergoes a change of control within 18 months of signing the transaction. That provision may preserve Haisco Pharmaceutical Group’s participation if ciprocopan makes Nuvectis Pharma an acquisition target, but it could also increase the effective transaction cost for a prospective buyer during the defined period.

Nuvectis Pharma moved quickly to strengthen its balance sheet after announcing the licensing transaction. The company sold five million shares at $20 per share in an underwritten public offering, generating $100 million in gross proceeds and an estimated $93 million in net proceeds before any exercise of the underwriters’ option. The financing increased the company’s share count from approximately 26.5 million to approximately 31.5 million on a pro forma basis, representing an increase of nearly 19% before accounting for other potential securities.

The offering prospectus indicated that cash, cash equivalents and short-term investments would have increased from $25.1 million at March 31, 2026 to approximately $118.1 million on an adjusted basis. Nuvectis Pharma intends to use the proceeds to advance NXP100, NXP200 and NXP900, hire personnel, fund capital expenditures and cover general corporate expenses. The larger balance sheet reduces near-term financing pressure, but the broad use-of-proceeds language means investors do not yet have a precise allocation showing how much capital will be committed specifically to ciprocopan’s global development.

Why Nuvectis Pharma stock remains cautious despite ciprocopan’s regulatory validation

Nuvectis Pharma shares were trading at approximately $18.86 at 11:53 a.m. Eastern Time on July 23, below the $20 offering price and nearly 34% below the $28.53 closing price recorded on June 29 before the offering was priced. Part of that decline reflects the substantial discount used to complete the financing and the dilution created by issuing five million new shares. The muted response to the China approval suggests that the market had already assigned meaningful value to ciprocopan or remains unwilling to reward the asset until Nuvectis Pharma provides a clearer ex-China regulatory plan.

The company’s market capitalization was approximately $440 million during Thursday trading. That valuation now reflects a business with a stronger balance sheet, an approved licensed asset, additional oncology programs and substantial future payment obligations. Investors are effectively weighing whether ciprocopan’s once-daily profile and Phase 3 performance can support a commercially meaningful position against Novartis, AstraZeneca and other companies developing complement pathway treatments.

The absence of an immediate stock rally is not necessarily evidence that the approval lacks value. China is outside Nuvectis Pharma’s commercial territory, and the company has not yet disclosed a detailed timeline for discussions with the United States Food and Drug Administration, European regulators or other major agencies. Questions also remain about whether existing Chinese studies will be sufficient, whether bridging or multinational trials will be required and how rapidly the company can assemble the regulatory, medical and commercial infrastructure needed for a global rare-disease program.

The approval nevertheless strengthens Nuvectis Pharma’s negotiating position. A drug with demonstrated Phase 3 efficacy and an initial marketing authorization is generally a more credible candidate for regional partnerships, sublicensing arrangements or strategic interest than an asset supported only by development-stage data. The company must now decide how much of the program it wants to control directly and where partnerships could reduce capital requirements without surrendering too much future economics.

The next valuation catalysts are likely to come from regulatory guidance outside China, the outcome of the second Chinese PNH application, publication or presentation of fuller Phase 3 data and the selection of additional complement-mediated indications. Evidence that the company can reuse Haisco Pharmaceutical Group’s clinical package efficiently would strengthen the return profile of the licensing deal. Requirements for major new trials would extend timelines, increase spending and place greater pressure on the recently raised capital.

Key takeaways from ciprocopan’s China approval and the Nuvectis Pharma investment outlook

• Ciprocopan’s first marketing approval materially reduces uncertainty around the molecule, but it does not guarantee approval by regulators in the United States, Europe or other Nuvectis Pharma territories.
• The head-to-head Phase 3 results against eculizumab provide a commercially relevant efficacy argument that could support regulatory discussions, partnerships and physician interest.
• Once-daily oral dosing may distinguish ciprocopan from Novartis’ twice-daily Fabhalta, although convenience alone will not overcome differences in regulatory status, safety evidence, pricing or market access.
• Nuvectis Pharma does not own the Chinese commercial rights, so the approval creates validation and strategic leverage rather than an immediate direct revenue stream from China.
• The Haisco Pharmaceutical Group agreement carries up to $40 million in upfront and early payments, up to $1.4 billion in additional milestones and tiered royalties, increasing the level of commercial success required to generate attractive returns.
• The $100 million equity offering gives Nuvectis Pharma more capital to advance NXP100 and its broader pipeline, but it also increased the outstanding share count and diluted existing investors.
• Nuvectis Pharma’s share price remaining below the $20 offering level indicates that investors want clearer evidence of the cost, timing and regulatory pathway for ciprocopan outside China.
• The most important next developments will be ex-China regulatory guidance, the second Chinese PNH decision, fuller disclosure of the Phase 3 package and details about which complement-mediated diseases Nuvectis Pharma will prioritize.